KLK3 and prostate carcinoma: In prostate cancer (PCa), alongside the well-known prostate-specific antigen (PSA), several reports have demonstrated the increased expression of the human epidermal growth factor receptor 2 (HER-2/neu) in patients with localized and more advanced hormone-resistant disease [6,7,8].